Clinical trial · Observational
Role of FDG-PET CT in the Management of Muscle Invasive Bladder Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Bladder cancer is the seventh cause of cancer mortality in France. Overall survival is poor, between 45 and 50% at 5 years. Optimal staging of lymph nodes and metastasis is crucial for treatment decision of muscle invasive bladder cancer (MIBC). Guidelines do not recommend FDG-Positron Emission Tomography (PET) Computed Tomography (CT), but rather CT for lymph node and metastatic staging, despite its low accuracy. We performed a retrospective analysis of patients undergoing PET CT for localized MIBC in two centers, to help define the utility of PET CT in this setting.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Muscle Invasive Bladder Cancer | Bladder Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PET CT | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- MIBC
- description
- Patients with muscle invasive bladder cancer (MIBC)
- interventionNames
- Device: PET CT
Primary outcomes (2)
- measure
- Accuracy of the PET CT for Lymph Node Staging in Terms of Sensitivy Rate
- timeFrame
- 16 weeks after inclusion
- description
- Performance sensitivity of FDG-PET CT for LN staging on diagnosis of MIBC (before and after NAC and before cystectomy and LN dissection). Gold standard : pathological results (complete response vs no complete response). Comparison of PET-CT TNM staging between patients with and patients without a Pathological Complete Response. Sensitivity rate : count of participants with complete response as per FDG-PET divided by count of participants with pathoplogical complete response
- measure
- Accuracy of the PET CT for Lymph Node Staging in Terms of Specificity Rate
- timeFrame
- Date of pathological results, up to 20 weeks after inclusion
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of Muscle Invasive Urothelial Carcinoma of the bladder (classified at least pT2 on TURB) * Diagnosis between January 2005 and December 2017 * PET CT done during initial assessment before surgery (at the time of diagnosis and/or after neoadjuvant chemotherapy) * Management of cancer at Institut Bergonié or at Bordeaux University Hospital * Previous treatment for Non Muscle Invasive Bladder Cancer allowed Exclusion Criteria: * Management of cancer outside of Institut Bergonié or Bordeaux University Hospital * No PET CT done during initial assessment (before surgery) * Rare pathological type of bladder cancer without urothelial carcinoma (epidermoid carcinoma, neuro-endocrine carcinoma, …) * Extra-vesical urothelial carcinoma
References
Publications (1)
- RESULTBertolaso P, Brouste V, Cazeau AL, de Clermont-Gallerande H, Bladou F, Cabart M, Lefort F, Gross-Goupil M. Impact of 18 FDG- PET CT in the Management of Muscle Invasive Bladder Cancer. Clin Genitourin Cancer. 2022 Jun;20(3):297-297.e6. doi: 10.1016/j.clgc.2022.01.009. Epub 2022 Jan 14. PMID 35101381